No

Antilipemic Agent (Bile Acid Seqestrant)

Adjunct in management of primary hypercholesterolemia; regression of arteriolosclerosis; relief of pruritus associated with elevated levels of bile acids; possibly used to decrease plasma half-life of digoxin in toxicity

C

Hypersensitivity of bile acid sequestering resins or any components of the products; bowel obstruction

Not to be taken simultaneously with many other medicines (decreased absorption). Treat any diseases contributing to hypercholesterolemia first. May interfere with fat soluble vitamins (A, D, E, K) and folic acid. Chronic use may be associated with bleeding problems. May produce or exacerbate constipation problems. Fecal impaction may occur. Hemorrhoids may be worsened.

>10%: Gastrointestinal: Constipation

1% to 10%:

Central nervous system: Headache, dizziness, anxiety, vertigo, drowsiness, fatigue

Gastrointestinal: Abdominal pain and distention, belching, flatulence, nausea, vomiting, diarrhea

<1% (Limited to important or life-threatening symptoms): Peptic ulceration, gallstones, GI irritation and bleeding, anorexia, steatorrhea or malabsorption syndrome, cholelithiasis, cholecystitis, shortness of breath

Symptoms of overdose include GI obstruction, nausea, GI distress

Treatment is supportive

Colestipol can reduce the absorption of numerous medications when used concurrently. Give other medications 1 hour before or 4 hours after giving colestipol. Medications which may be affected include HMG-CoA reductase inhibitors, thiazide diuretics, propranolol (and potentially other beta-blockers), corticosteroids, thyroid hormones, digoxin, valproic acid, NSAIDs, loop diuretics, sulfonylureas, troglitazone (and potentially other agents in this class).

Warfarin and other oral anticoagulants: Absorption is reduced by cholestyramine, may also be reduced by colestipol. Separate administration times (as detailed above) and monitor INR closely when initiating or discontinuing.

Binds with bile acids to form an insoluble complex that is eliminated in feces; it thereby increases the fecal loss of bile acid-bound low density lipoprotein cholesterol

Absorption: Oral: Not absorbed

Adults: Oral:

Tablets: 2-16 g/day; initial dose: 2 g 1-2 times/day; increase by 2 g at 1- to 2-month intervals

prothrombin time; cholesterol (S)

Colestipol alone or when combined with a statin is effective in lowering cholesterol. Colestipol may increase triglycerides, therefore, it should be avoided in patients with triglyceride levels greater than or equal to 200 mg/dL. Potential factors that may limit patient compliance include GI side effects and the need to space other medications at least 1 hour before or 4 hours after colestipol administration.

May cause drowsiness or anxiety

Constipation is common; may be exacerbated by concurrent psychotropic use; may decrease the absorption of TCAs

No information available to require special precautions

No effects or complications reported

Take with 38-45 ounces of water or fruit juice. Rinse glass with small amount of water to ensure full dose is taken. Other medications should be taken 2 hours before or 2 hours after colestipol. You may experience constipation (increased exercise, increased dietary fluids, fruit, fiber, or stool softener may help) or drowsiness or dizziness (use caution when driving or engaging in tasks that require alertness until response to drug is known). Report acute gastric pain, tarry stools, or difficulty breathing. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Breast-feeding is not recommended.

Dry powder should be added to at least 90 mL of liquid and stirred until completely mixed; other drugs should be administered at least 1 hour before or 4 hours after colestipol

Granules, as hydrochloride: 5 g packet, 300 g, 500 g

Tablet, as hydrochloride: 1 g